These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 28557813)

  • 21. The incidence and relative risk of pulmonary toxicity in patients treated with anti-PD1/PD-L1 therapy for solid tumors: a meta-analysis of current studies.
    Ciccarese C; Iacovelli R; Bria E; Modena A; Massari F; Brunelli M; Fantinel E; Bimbatti D; Zamboni GA; Artibani W; Tortora G
    Immunotherapy; 2017 Jun; 9(7):579-587. PubMed ID: 28595514
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nivolumab instills hope in a hopeless situation in advanced nonsmall cell lung cancer with poor performance status.
    Chandrakanth MV; Noronha V; Joshi A; Patil V; Mahajan A; Prabhash K
    Indian J Cancer; 2017; 54(1):55-56. PubMed ID: 29199664
    [No Abstract]   [Full Text] [Related]  

  • 23. Severe Thrombocytopenia Associated With Pembrolizumab in Patients With Non-small Cell Lung Cancer (NSCLC): A Case Report and Literature Review.
    Mouri A; Kaira K; Shiono A; Miura YU; Kagamu H
    In Vivo; 2020; 34(2):877-880. PubMed ID: 32111798
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer.
    Dang TO; Ogunniyi A; Barbee MS; Drilon A
    Expert Rev Anticancer Ther; 2016; 16(1):13-20. PubMed ID: 26588948
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Indirect comparison between pembrolizumab and nivolumab for the treatment of non-small cell lung cancer: A meta-analysis of randomized clinical trials.
    Peng TR; Tsai FP; Wu TW
    Int Immunopharmacol; 2017 Aug; 49():85-94. PubMed ID: 28554108
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A rapid response to pembrolizumab in a patient with metastatic melanoma.
    Bayo Calero J; Aviñó Tarazona V
    Immunotherapy; 2017 Mar; 9(3):225-228. PubMed ID: 28231724
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pembrolizumab (Keytruda) for first-line treatment of metastatic NSCLC.
    Med Lett Drugs Ther; 2017 Jan; 59(1513):22-23. PubMed ID: 28118650
    [No Abstract]   [Full Text] [Related]  

  • 28. Anti-PD-1-Related Exacerbation of Interstitial Lung Disease in a Patient with Non-Small Cell Lung Cancer: A Case Presentation and Review of the Literature.
    L Gemmill JA; Sher A
    Cancer Invest; 2020 Jul; 38(6):365-371. PubMed ID: 32559143
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recurrent dysphasia due to nivolumab-induced encephalopathy with presence of Hu autoantibody.
    Raskin J; Masrori P; Cant A; Snoeckx A; Hiddinga B; Kohl S; Janssens A; Cras P; Van Meerbeeck JP
    Lung Cancer; 2017 Jul; 109():74-77. PubMed ID: 28577954
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-PD-1 pembrolizumab induced autoimmune diabetes in Chinese patient: A case report.
    Li S; Zhang Y; Sun Z; Hu J; Fang C
    Medicine (Baltimore); 2018 Nov; 97(45):e12907. PubMed ID: 30407284
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advances in the Treatment of Non-small Cell Lung Cancer: Focus on Nivolumab, Pembrolizumab, and Atezolizumab.
    Leventakos K; Mansfield AS
    BioDrugs; 2016 Oct; 30(5):397-405. PubMed ID: 27411930
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Scleroderma Induced by Pembrolizumab: A Case Series.
    Barbosa NS; Wetter DA; Wieland CN; Shenoy NK; Markovic SN; Thanarajasingam U
    Mayo Clin Proc; 2017 Jul; 92(7):1158-1163. PubMed ID: 28599746
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Life threatening pembrolizumabinduced myositis in a patient treated for advanced adenocarcinoma of the lung.
    Robinson SD; Lai C; Hotton G; Anand G
    Acute Med; 2019; 18(3):197-199. PubMed ID: 31536059
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enteric plexus neuropathy associated with PD-L1 blockade in a patient with small-cell lung cancer.
    Trontzas IP; Rapti VE; Syrigos NK; Kounadis G; Perlepe N; Kotteas EA; Bamias G
    Immunotherapy; 2021 Sep; 13(13):1085-1092. PubMed ID: 34247513
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aggravation of depigmentation for a non-small-cell lung cancer patient with pre-existing vitiligo using anti-programmed cell death-1 therapy: case report.
    Xu Y; Cai Y; Zu J; Wang X; Wang Y; Sun C; Guo Y; Shao G; Yang Z; Qiu S; Ma K
    Immunotherapy; 2020 Feb; 12(3):175-181. PubMed ID: 32064977
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression.
    Wen L; Zou X; Chen Y; Bai X; Liang T
    Front Immunol; 2020; 11():2076. PubMed ID: 32973816
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Not Available].
    Fabre E; Pécuchet N; Cadranel J
    Bull Cancer; 2016 Nov; 103 Suppl 1():S138-S143. PubMed ID: 28057177
    [TBL] [Abstract][Full Text] [Related]  

  • 38. COVID-19: the use of immunotherapy in metastatic lung cancer.
    Davis AP; Boyer M; Lee JH; Kao SC
    Immunotherapy; 2020 Jun; 12(8):545-548. PubMed ID: 32349579
    [No Abstract]   [Full Text] [Related]  

  • 39. Sintilimab induced diabetic ketoacidosis in a patient with small cell lung cancer: A case report and literature review.
    Huang X; Yang M; Wang L; Li L; Zhong X
    Medicine (Baltimore); 2021 May; 100(19):e25795. PubMed ID: 34106616
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diabetic ketoacidosis induced by a single dose of pembrolizumab.
    Maamari J; Yeung SJ; Chaftari PS
    Am J Emerg Med; 2019 Feb; 37(2):376.e1-376.e2. PubMed ID: 30361152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.